NL-OMON50777已完成不适用
ongkankernet implementation ctDNA Analysis - LICA
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 250
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •Patients with confirmed or suspected non-small cell lung cancer
- •Signed informed consent
- •Adult (>= 18 years of age) and mentally competent
排除标准
- •Patients with a benign lesion
- •Patients with a metastasis of another primary cancer than lung cancer
研究者
相似试验
招募中
不适用
Implementation of up-front ctDNA analysis into lung cancer care and development of liquid biopsy-based decision support models - the Lungmarker2 studylung carcinoma10029107lung cancerNL-OMON53764Catharina-ziekenhuis800
已完成
不适用
TLA Technology: a new DNA diagnostic test to sequence genes that cause the disease and detect new mutations: proof of concept study voor patients with Rendu-Osler-Weber disease.Rendu-Osler-Weber hereditary hemorrhagic telangiectasia10007510NL-OMON39779Sint Antonius Ziekenhuis45
招募中
不适用
Dynamic liquid molecular profiling in anaplastic lymphoma kinase (ALK) Non-Small Cell Lung CancerAdvanced ALK+ NSCLCCancer - Lung - Non small cellACTRN12623000226606Peter MacCallum Cancer Centre55
进行中（未招募）
1 期
A trial using ctDNA mutation tracking to detect cancer cells in the blood of patients with triple negative breast cancer who have completed standard treatmentEarly stage triple negative breast cancerMedDRA version: 20.0Level: PTClassification code 10006187Term: Breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2017-000508-92-GBThe Institute of Cancer Research150
招募中
2 期
Track and treat in NSCLC (TATIN) - ctDNA guided treatment of early resistance to targeted treatment in patients with EGFR positive NSCLCnon-small cell lung cancerLung cancerNL-OMON48173Antoni van Leeuwenhoek Ziekenhuis30